Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA) and Xenon (XENE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ginkgo Bioworks Holdings (DNA – Research Report) and Xenon (XENE – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ginkgo Bioworks Holdings (DNA)
TD Cowen analyst Brendan Smith maintained a Buy rating on Ginkgo Bioworks Holdings yesterday and set a price target of $12.00. The company’s shares closed last Thursday at $9.71, close to its 52-week low of $5.26.
According to TipRanks.com, Smith is a 3-star analyst with an average return of
Currently, the analyst consensus on Ginkgo Bioworks Holdings is a Moderate Buy with an average price target of $12.00.
See Insiders’ Hot Stocks on TipRanks >>
Xenon (XENE)
TD Cowen analyst Joseph Thome maintained a Buy rating on Xenon yesterday. The company’s shares closed last Thursday at $44.92, close to its 52-week high of $46.00.
According to TipRanks.com, Thome is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xenon with a $55.63 average price target, representing a 24.8% upside. In a report issued on February 23, Wolfe Research also initiated coverage with a Buy rating on the stock with a $60.00 price target.
